GLP-1 Receptor Genes Track With Male Pattern Hair Loss

Men genetically prone to male pattern baldness face a 7 percent extra hair-loss risk tied to GLP-1 receptor activity. NYU Langone Health researchers reported that finding on September 3 in the Journal of Investigative Dermatology.

They did not follow patients on Ozempic, Wegovy, or Zepbound. They used gene variants that raise GLP-1 receptor levels as a stand-in for the drugs, and that overlap is the part the scare headlines skip.

A Gene Proxy for the Weight-Loss Shot

Senior investigator Lynn Petukhova, PhD, an assistant professor in dermatology and population health at NYU Grossman School of Medicine, led a two-sample Mendelian randomization analysis. The paper’s title states a causal effect of increased GLP1R expression on male pattern hair loss is suggested, not proven in a clinic.

GLP1R is the gene that helps set how many GLP-1 receptor proteins a person makes. Those receptors are the docking sites the hormone, and the drugs that mimic it, use to signal fullness. More receptors can make a GLP-1 medicine work more efficiently for weight loss. The same higher-activity versions of the gene showed up more often in men who also carry androgenetic alopecia, the inherited receding pattern along the front and top of the scalp.

NYU Langone’s release put that overlap as a 7 percent added risk of hair loss in men already genetically prone to the common form. The team adjusted for high blood pressure, which can cut scalp blood flow, and the 7 percent figure held. Insulin resistance and lower testosterone did not wipe it out either.

Our study provides the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically.

Lynn Petukhova, PhD, NYU Grossman School of Medicine

The DNA came from public datasets, not from a new trial of the pens. One was the eQTLGen resource of 31,684 mostly White men and women. The other was a Complex Traits Genetics set of 205,327 mostly White men. Male pattern hair loss is mapped well enough to test. Female pattern hair loss is not, which is why the causal analysis stopped at men.

WHAT THE GENE TEST CAN AND CANNOT SAY

• The method: Variants that raise GLP1R activity stood in for the biological effect of GLP-1 drugs.
• The overlap: Those variants were more common in men with androgenetic alopecia genes.
• The gap: No one in this paper was followed while taking Ozempic, Wegovy, or Zepbound.
• The ancestry limit: Both databases are mostly White, so the 7 percent figure is not a global rate.

Petukhova said it was surprising that, for some men already wired for male pattern hair loss, Ozempic or Wegovy could trigger or expose that susceptibility. That is a different claim from “the shot made a full head of hair fall out.”

The Same Receptor Tracks With Male Pattern Baldness

GLP-1 is a gut hormone released after food. The drugs copy it so the brain gets a fullness signal even when the plate is still full. Receptor count is not the same thing as hormone output. Extra receptors just give the drug more places to bind.

That is why the genetics are awkward for anyone chasing a simple side-effect story. The men whose receptor biology may help the medicine work are the same men whose hair-loss genes travel with that receptor activity. Efficacy and the hairline share a pathway on paper. The team has not shown how the pathway weakens a follicle, and Petukhova said that mechanism work still has to be done.

Androgenetic alopecia is already common without any pen in the drawer. NYU Langone’s hair-loss pages put the U.S. burden at more than 50 million men and 30 million women. A StatPearls review on the National Library of Medicine bookshelf says the condition reaches about 50 percent of Caucasian men by age 50, and about 80 percent by 70. The NYU release used a similar mark: half of White American men over 50, and nearly the same share of White American women over 50, mostly after menopause.

Layer a 7 percent extra genetic risk on that base and you still do not get a baldness epidemic from one prescription. You get a modest nudge in a group that was already going to thin.

How Fast Weight Loss Differs From Pattern Baldness

Until this paper, thinning on a GLP-1 was usually blamed on speed. Drop a lot of weight in a short window and hair follicles can shift from growth into rest, then shed in clumps two or three months later. That shed is telogen effluvium. It is diffuse. It is often temporary. Users have watched growth resume several months after the scale steadies, which is why so many clinicians treated “Ozempic hair” as a calorie problem.

On NYU Langone’s own condition pages, telogen effluvium usually begins three months later after a medical jolt, and hair may grow back after six months if the trigger eases. Pattern baldness does not wait on a protein shake. It follows a family map along the crown and temples and keeps going unless it is treated.

THE TWO HAIR PROBLEMS

A short shed and a receding pattern can also stack. A hard calorie cut can unmask a hairline that was already genetically thin. People arguing online still treat skipped protein as the whole case, as if a multivitamin closed the file. The NYU work says some of the risk sits in receptor genes even after you account for diabetes biology and testosterone.

Hair Loss Hit 3.3% in Wegovy Adult Trials

Hair thinning was not invented in a genetics lab in 2026. Novo Nordisk’s Wegovy label, posted on DailyMed, already counts hair loss in Wegovy’s adult trial pool and ties those reports to weight reduction.

HAIR LOSS IN WEGOVY TRIALS

The sex split is the tell. In that adult pool, 4 percent of women on the 2.4 mg dose reported hair loss, against 0.9 percent of men. Placebo women reported 2 percent. Placebo men reported none. If the only story were male pattern genes, the trial table would not look like that.

A separate FDA Adverse Event Reporting System review in the Journal of Cosmetic Dermatology, covering 2016 through 2025, found statistically notable alopecia signals only for semaglutide and tirzepatide, the molecules in Ozempic, Wegovy, Mounjaro, and Zepbound. Older GLP-1 drugs in the same scan did not clear the signal bar. Among reports with enough follow-up, 25 percent of semaglutide cases noted improvement after the drug was stopped. FAERS cannot give an incidence rate, and extra media attention after a 2023 FDA advisory can inflate reports. It still matches the trial table on one point: the hair complaint is already in the file.

Pair the Shot With a Hair Drug

Petukhova does not want people to drop a drug that is helping them. She does want a dermatologist in the room if the shed is heavy, because a clinic can tell a short telogen dump from patterned thinning and can add a preventive such as minoxidil.

WHAT A DERMATOLOGIST IS FOR

• The pattern: Diffuse clumps after a big weight drop point one way; a family hairline points another.
• The timing: A shed that starts about three months in fits telogen effluvium more than a slow crown fade.
• The add-on: Petukhova said GLP-1 users could be prescribed combination treatment, including minoxidil or another hair drug, if later tests support screening.

She also sketched a future in which some men, and possibly women, get benchmarked for hair-loss risk before the first pen. That screening does not exist as a standard order. It is a research hope sitting on top of a 7 percent genetic nudge.

The commercial tail is obvious without dressing it up. Minoxidil, finasteride, and hair clinics already live on androgenetic alopecia. A weight-loss drug used by a double-digit share of adults feeds that same waiting room, including people who will not quit the shot because the metabolic gains are large.

More Than 75% of Alopecia Reports Come From Women

The genetic proof is male. The complaint file is not. In the FAERS alopecia set, more than 75 percent of patients were women. Mean ages sat in the mid-50s. Consumers, not doctors, filed most of the reports.

WHERE THE HAIR SIGNAL SITS

• Who reports: More than 75 percent of FAERS alopecia cases tied to these drugs were women.
• Which drugs: Signals rose for semaglutide and tirzepatide; the 2025 tirzepatide reporting odds ratio reached 2.08.
• Who was studied: NYU could test a causal genetic link only in men, because female hair-loss genes are less mapped.
• Who uses the shots: A Gallup poll found current adult use for weight loss at 11 percent, up from 3 percent in 2024.

Women have been logging thinning on these drugs in patient forums for years, often next to low protein intake and iron problems. The new paper cannot yet say whether their GLP1R biology matches the male overlap. Petukhova has said she plans to test whether the male links apply to women. Until that lands, the group filling most of the adverse-event stack is the group this study could not analyze.

Stay on the Drug, the Geneticist Says

The user base is no longer a niche diabetes panel. Gallup’s National Health and Well-Being Index, from a web survey of 5,065 U.S. adults conducted May 28 to June 5, found that 15 percent of U.S. adults have used a GLP-1 for weight loss at some point, with 11 percent taking one now. Current use was 3 percent in 2024. Awareness of the drugs for weight loss reached 91 percent, up from 80 percent in 2024. Brand-name pens such as Ozempic or Wegovy made up 68 percent of current use; compounded or custom-mixed versions made up 19 percent, with 12 percent unsure.

Wegovy won FDA weight-loss approval in 2021. Eli Lilly’s Zepbound followed in November 2023. Over the same era, Gallup’s adult obesity rate slipped from 39.9 percent in 2022 to 36.4 percent in 2026. Hair is not the reason those numbers moved. It is the side effect that makes some users consider stopping anyway.

I don’t want GLP-1 users to stop using a medication that’s helping them because there are a lot of health benefits to these drugs. And also what our data suggests is that it is a very small number of people who will experience this.

Lynn Petukhova, PhD, to interviewers discussing the study

The National Institutes of Health funded the work through grants R01AR080796 and K01AR075111. Co-investigators included hair-loss physicians Jerry Shapiro, MD, and Kristen Lo Sicco, MD, at NYU Langone, with outside authors at the University of Pennsylvania, King’s College London, and Columbia. The mechanism that would turn extra receptor activity into a weaker follicle is still unmapped. So is the female genetic file. The 7 percent extra risk is real as a gene-level finding and small as a reason to abandon a drug that is otherwise working.

Disclaimer: This article is news reporting on a published genetics paper and related drug-label and survey figures. It is informational only and is not medical advice, a diagnosis, or a recommendation to start, stop, or combine any GLP-1 medicine, minoxidil, or other hair treatment. Readers should talk with a licensed physician or dermatologist who knows their history before changing a prescription or treating hair loss. Figures and study conclusions reflect the sources dated in the piece and may change as later trials and female-specific genetic tests appear.